Cuihua Yi

Nov 1, 2024 | jitc.bmj.com | Bin Lian |Yu Chen |Meiyu Fang |Cuihua Yi

Late-Breaking AbstractsClinical Trial In Progress 1502 Efficacy and safety results of first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein IBI363 in patients with immunotherapy-naïve advanced melanoma Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service.